Spots Global Cancer Trial Database for her2 gene mutation
Every month we try and update this database with for her2 gene mutation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | NCT03602079 | HER2-positive B... HER2 Gene Mutat... HER-2 Gene Ampl... HER2 Positive G... Salivary Gland ... Salivary Gland ... Salivary Gland ... Salivary Gland ... Lung Cancer Colo-rectal Can... Rare Diseases Solid Tumor Recurrent Gastr... Recurrent Colon... Recurrent Breas... Head and Neck C... Head and Neck C... Bladder Cancer Cervical Cancer Liver Cancer Bile Duct Cance... Urologic Cancer Pancreatic Canc... Prostate Cancer Recurrent Prost... Rectal Cancer Recurrent Ovari... Recurrent Renal... Rectal Cancer S... Rectal Cancer S... Rectal Cancer S... Skin Cancer Mouth Cancer Lip Cancer Stag... Tongue Cancer Breast Neoplasm... Larynx Cancer Tonsil Cancer Palate Cancer Mucoepidermoid ... Primary Periton... Mucinous Adenoc... Mucinous Breast... Cholangiocarcin... | A166 | 18 Years - | Klus Pharma Inc. | |
| Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | NCT06282575 | Biliary Tract C... HER2 Gene Mutat... | Zanidatamab Cisplatin Gemcitabine Pembrolizumab Durvalumab | 18 Years - | Jazz Pharmaceuticals | |
| Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas | NCT04620187 | Salivary Gland ... HER2 Gene Mutat... | Ado-trastuzumab... Standard of Car... Standard of Car... | 18 Years - | Dana-Farber Cancer Institute | |
| The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor | NCT04179656 | Solid Tumor HER2 Gene Mutat... HER-2 Gene Ampl... HER-2 Protein O... | Pyrotinib | 18 Years - 75 Years | Tianjin Medical University Second Hospital | |
| Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas | NCT04620187 | Salivary Gland ... HER2 Gene Mutat... | Ado-trastuzumab... Standard of Car... Standard of Car... | 18 Years - | Dana-Farber Cancer Institute | |
| Neratinib and Trastuzumab Biosimilar in Patients With HER2 Mutated Advanced Solid Cancers | NCT06083662 | Metastatic Canc... HER2 Gene Mutat... | Neratinib Malea... | 19 Years - | Korea University Guro Hospital | |
| Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors | NCT05511844 | HER2-positive B... HER-2 Protein O... HER-2 Gene Ampl... HER2 Gene Mutat... | ORM-5029 | 18 Years - | Orum Therapeutics USA, Inc. | |
| Her2-positive Lung Cancer Treated With Dedicated Drug | NCT03845270 | Non Small Cell ... Non Small Cell ... HER2 Gene Mutat... | pertuzumab + tr... | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer | NCT03412383 | Breast Cancer HER2 Gene Mutat... | Pyrotinib | 18 Years - 70 Years | Peking Union Medical College | |
| Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001) | NCT02979821 | HER2 Gene Mutat... Adenocarcinoma ... | Poziotinib | - | Korean Association for the Study of Targeted Therapy | |
| Neratinib and Trastuzumab Biosimilar in Patients With HER2 Mutated Advanced Solid Cancers | NCT06083662 | Metastatic Canc... HER2 Gene Mutat... | Neratinib Malea... | 19 Years - | Korea University Guro Hospital | |
| Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer | NCT06178445 | Biliary Tract C... HER2 Gene Mutat... | SOC plus trastu... | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | NCT06282575 | Biliary Tract C... HER2 Gene Mutat... | Zanidatamab Cisplatin Gemcitabine Pembrolizumab Durvalumab | 18 Years - | Jazz Pharmaceuticals | |
| Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma | NCT06383533 | Bile Duct Adeno... HER2 Gene Mutat... | Disitamab Vedot... | 18 Years - | Zhejiang Cancer Hospital | |
| Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors | NCT05511844 | HER2-positive B... HER-2 Protein O... HER-2 Gene Ampl... HER2 Gene Mutat... | ORM-5029 | 18 Years - | Orum Therapeutics USA, Inc. | |
| Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer | NCT03412383 | Breast Cancer HER2 Gene Mutat... | Pyrotinib | 18 Years - 70 Years | Peking Union Medical College |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
